These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 11602042)

  • 1. Emergence of drug resistance mutations in a group of HIV-infected children taking nelfinavir-containing regimens.
    Fitzgibbon JE; Gaur S; Walsman SM; Janahi M; Whitley-Williams P; John JF
    AIDS Res Hum Retroviruses; 2001 Sep; 17(14):1321-8. PubMed ID: 11602042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine.
    Atkinson B; Isaacson J; Knowles M; Mazabel E; Patick AK
    J Infect Dis; 2000 Aug; 182(2):420-7. PubMed ID: 10915071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).
    Pellegrin I; Breilh D; Montestruc F; Caumont A; Garrigue I; Morlat P; Le Camus C; Saux MC; Fleury HJ; Pellegrin JL
    AIDS; 2002 Jul; 16(10):1331-40. PubMed ID: 12131209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART.
    Røge BT; Katzenstein TL; Nielsen HL; Gerstoft J
    HIV Med; 2003 Jan; 4(1):38-47. PubMed ID: 12534958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
    Albrecht MA; Bosch RJ; Hammer SM; Liou SH; Kessler H; Para MF; Eron J; Valdez H; Dehlinger M; Katzenstein DA;
    N Engl J Med; 2001 Aug; 345(6):398-407. PubMed ID: 11496850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Puthanakit T; Jourdain G; Hongsiriwon S; Suntarattiwong P; Chokephaibulkit K; Sirisanthana V; Kosalaraksa P; Petdachai W; Hansudewechakul R; Siangphoe U; Suwanlerk T; Ananworanich J;
    HIV Med; 2010 Oct; 11(9):565-72. PubMed ID: 20345882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations.
    Núńez M; de Mendoza C; Valer L; Casas E; López-Calvo S; Castro A; Rosón B; Podzamczer D; Rubio A; Berenguer J; Soriano V
    Med Sci Monit; 2002 Sep; 8(9):CR620-3. PubMed ID: 12218942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.
    Starr SE; Fletcher CV; Spector SA; Yong FH; Fenton T; Brundage RC; Manion D; Ruiz N; Gersten M; Becker M; McNamara J; Mofenson LM; Purdue L; Siminski S; Graham B; Kornhauser DM; Fiske W; Vincent C; Lischner HW; Dankner WM; Flynn PM
    N Engl J Med; 1999 Dec; 341(25):1874-81. PubMed ID: 10601506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir.
    Svedhem V; Lindkvist A; Bergroth T; Knut L; Sönnerborg A
    J Med Virol; 2005 Aug; 76(4):447-51. PubMed ID: 15977242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic HIV-1 resistance correlates with treatment outcome of nelfinavir salvage therapy.
    Walter H; Schmidt B; Rascu A; Helm M; Moschik B; Paatz C; Kurowski M; Korn K; Uberla K; Harrer T
    Antivir Ther; 2000 Dec; 5(4):249-56. PubMed ID: 11142619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir.
    Tebas P; Patick AK; Kane EM; Klebert MK; Simpson JH; Erice A; Powderly WG; Henry K
    AIDS; 1999 Feb; 13(2):F23-8. PubMed ID: 10202820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
    Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
    N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HIV genotypic mutation selectively induced by the protease inhibitor nelfinavir at codon 30. Case series and consequences for antiretroviral management].
    Manfredi R; Calza L
    Infez Med; 2002 Sep; 10(3):151-6. PubMed ID: 12704265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy.
    Kakehasi FM; Tupinambás U; Cleto S; Aleixo A; Lin E; Melo VH; Aguiar RA; Pinto JA
    AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1515-20. PubMed ID: 18160009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective comparison of first-line nelfinavir therapy versus nelfinavir introduction in rescue antiretroviral regimens.
    Manfredi R; Calza L; Chiodo F
    AIDS Patient Care STDS; 2003 Mar; 17(3):105-14. PubMed ID: 12724006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary nelfinavir (NFV)-associated resistance mutations during a follow-up period of 108 weeks in protease inhibitor naïve patients treated with NFV-containing regimens in an HIV clinic cohort.
    Tsuchiya K; Matsuoka-Aizawa S; Yasuoka A; Kikuchi Y; Tachikawa N; Genka I; Teruya K; Kimura S; Oka S
    J Clin Virol; 2003 Aug; 27(3):252-62. PubMed ID: 12878089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens.
    Hall CS; Raines CP; Barnett SH; Moore RD; Gallant JE
    AIDS; 1999 Jul; 13(10):1207-12. PubMed ID: 10416524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
    West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene.
    Dronda F; Casado JL; Moreno S; Hertogs K; García-Arata I; Antela A; Pérez-Elías MJ; Ruiz L; Larder B;
    AIDS Res Hum Retroviruses; 2001 Feb; 17(3):211-5. PubMed ID: 11177403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.